Por: NotebookLM

Nirsevimab effectiveness, number needed to immunize and impact on severeRSV outcomes in preterm, high-risk and healthy-term infants, Quebec,CanadaSara Carazo, MD PhD1,2,3 – Manale Ouakki, MSc3 – Danuta M Skowronski, MD FRCPC4 –Maude Paquette, MD5,6,7 – Nicholas Brousseau, MD MSc FRCPC1,2,3 – Denis Talbot,PhD1,2 – Charles-Antoine Guay, MD MSc1,3 – Caroline Quach, MD MSc5,6 – Rodica Gilca,MD PhD1,2,3 – Jesse Papenburg, MD MSc8,91Social and preventive medicine department, Faculty of medicine, Laval University, Québec,Québec, Canada2Centre Hospitalier Universitaire (CHU) de Québec–Université Laval Research Center, Québec,Québec, Canada3Biological risk unit. Institut national de santé publique du Québec, Québec, Québec, Canada4Communicable Diseases and Immunization Services, BC Centre for Disease Control, Vancouver,British Columbia, Canada5Department of Microbiology, University of Montreal, Montréal, Canada6Clinical Department of Laboratory Medicine, CHU Sainte-Justine, Montréal, Québec, Canada7Laboratoire de santé publique du Québec, Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada8Departement of pediatric, Montreal Children's Hospital of the McGill university Health Centre,Montréal, Québec, Canada9Departement of epidemiology, biostatistics and occupational health, Université McGill, Montréal,Québec, CanadaCorresponding author:Sara CarazoDepartment of social and preventive medicine, Laval UniversityInstitut national de santé publique du Québec945 Wolfe Avenue, Quebec City, QC, Canada, G1V 5B3+1 418 650 [email protected]; [email protected]

1 episodios disponibles